Cell therapy for Parkinson's disease with induced pluripotent stem cells

1. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al.

Transplantation of embryonic dopamine neurons for severe Parkinson’s

disease. N Engl J Med. 2001;344(10):710–9.

2. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A

double-blind controlled trial of bilateral fetal nigral transplantation in

Parkinson’s disease. Ann Neurol. 2003;54(3):403–14.

3. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson’s disease:

problems and possibilities. Prog Brain Res. 2010;184:265–94.

Morizane Inflammation and Regeneration

(2023) 43:16

4. Mendez I, Sanchez-Pernaute R, Cooper O, Viñuela A, Ferrari D, Björklund L,

et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s

disease. Brain. 2005;128(Pt 7):1498–510.

5. Adler AF, Cardoso T, Nolbrant S, Mattsson B, Hoban DB, Jarl U, et al. hESCderived dopaminergic transplants integrate into basal ganglia circuitry

in a preclinical model of Parkinson’s disease. Cell Rep. 2019;28(13):3462–

3473.e5.

6. Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, et al. Human

iPS cell-derived dopaminergic neurons function in a primate Parkinson’s

disease model. Nature. 2017;548(7669):592–6.

7. Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K, et al. Preclinical study of induced pluripotent stem cell-derived dopaminergic

progenitor cells for Parkinson’s disease. Nat Commun. 2020;11(1):3369.

8. Kim TW, Piao J, Koo SY, Kriks S, Chung SY, Betel D, et al. Biphasic activation

of WNT signaling facilitates the derivation of midbrain dopamine neurons

from hESCs for translational use. Cell Stem Cell. 2021;28(2):343–355.e5.

9. Piao J, Zabierowski S, Dubose BN, Hill EJ, Navare M, Claros N, et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain

dopamine progenitor product, MSK-DA01. Cell Stem Cell. 2021;28(2):217–

229.e7.

10. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with

neural transplants. Sci Transl Med. 2010;2(38):38ra46.

11. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M,

et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014;71(1):83–7.

12. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M,

Studer L. Highly efficient neural conversion of human ES and iPS cells by

dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275–80.

13. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports.

2014;2(3):337–50.

14. Samata B, Doi D, Nishimura K, Kikuchi T, Watanabe A, Sakamoto Y, et al.

Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. Nat Commun. 2016;7:13097.

15. Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune

privilege. Trends Immunol. 2015;36(10):569–77.

16. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic

donors. Blood. 2013;122(8):1341–9.

17. Rong Z, Wang M, Hu Z, Stradner M, Zhu S, Kong H, et al. An effective

approach to prevent immune rejection of human ESC-derived allografts.

Cell Stem Cell. 2014;14(1):121–30.

18. Gornalusse GG, Hirata RK, Funk SE, Riolobos L, Lopes VS, Manske G, et al.

HLA-E-expressing pluripotent stem cells escape allogeneic responses

and lysis by NK cells. Nat Biotechnol. 2017;35(8):765–72.

19. Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, et al. Targeted

disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced

immune compatibility. Cell Stem Cell. 2019;24(4):566–578.e7.

20. Takahashi J. iPS cell-based therapy for Parkinson’s disease: a Kyoto trial.

Regenerative Ther. 2020;13:18–22.

21. Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N

Engl J Med. 2020;382(20):1926–32.

22. Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, et al. Direct

comparison of autologous and allogeneic transplantation of iPSCderived neural cells in the brain of a nonhuman primate. Stem Cell Rep.

2013;1(4):283–92.

23. Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H, et al. MHC

matching improves engraftment of iPSC-derived neurons in non-human

primates. Nat Commun. 2017;8(1):385.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Page 5 of 5

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission

• thorough peer review by experienced researchers in your field

• rapid publication on acceptance

• support for research data, including large and complex data types

• gold Open Access which fosters wider collaboration and increased citations

• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

...